Virological responses during treatment for recent hepatitis C virus: Potential benefit for ribavirin use in HCV/HIV co-infection

AIDS

Volumn 26, Issue 13, 2012, Pages 1653-1661

  Grebely, Jason ^a   Hellard, Margaret ^b,c   Applegate, Tanya ^a   Petoumenos, Kathy ^a   Yeung, Barbara ^a   Feld, Jordan J ^d   Rawlinson, William ^e   Lloyd, Andrew R ^f   George, Jacob ^g   Kaldor, John M ^a   Dore, Gregory J ^a,h   Matthews, Gail V ^a,h  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b BURNET INSTITUTE   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d UNIVERSITY OF TORONTO   (Canada)

^e PRINCE OF WALES HOSPITAL   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h ST VINCENT S HOSPITAL   (Australia)

Author keywords

acute; HIV; IL28B; pegylated interferon; therapy

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PATIENT COMPLIANCE; PREDICTOR VARIABLE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; AUSTRALIA; COINFECTION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV; HIV SEROPOSITIVITY; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LOGISTIC MODELS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84865483812     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283553719     Document Type: Article

References (35)

1. Danta M, Rodger AJ. Transmission of HCV in HIV-positive populations. Curr Opin HIV AIDS 2011; 6:451-458.
2. Jin F, Prestage GP, Matthews G, Zablotska I, Rawstorne P, Kippax SC, et al. Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIVnegative and HIV-positive men in Sydney, Australia. Sex Transm Infect 2010; 86:25-28.
3. Rauch A, Rickenbach M, Weber R, Hirschel B, Tarr PE, Bucher HC, et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis 2005; 41:395-402. (Pubitemid 41022120)
4. van de Laar TJ, van der Bij AK, Prins M, Bruisten SM, Brinkman K, Ruys TA, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007; 196:230-238. (Pubitemid 47047462)
5. Taylor LE, Holubar M, Wu K, Bosch RJ, Wyles DL, Davis JA, et al. Incident hepatitis C virus infection among US HIVinfected men enrolled in clinical trials. Clin Infect Dis 2011; 52:812-818.
6. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21:983-991. (Pubitemid 46684329)
7. Calleri G, Cariti G, Gaiottino F, De Rosa FG, Bargiacchi O, Audagnotto S, et al. A short course of pegylated interferonalpha in acute HCV hepatitis. J Viral Hepat 2007; 14:116-121. (Pubitemid 46146706)
8. Broers B, Helbling B, Francois A, Schmid P, Chuard C, Hadengue A, et al. Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 2005; 42:323-328. (Pubitemid 40254245)
9. Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, Peters T, et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 2004; 39:1721-1731. (Pubitemid 38702674)
10. Kamal SM, Moustafa KN, Chen J, Fehr J, Abdel Moneim A, Khalifa KE, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 2006; 43:923-931. (Pubitemid 43724617)
11. Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006; 130:632-638. (Pubitemid 43374512)
12. Santantonio T, Fasano M, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 2005; 42:329-333. (Pubitemid 40254246)
13. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006; 43:250-256.
14. Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010; 138:123-135; e121-122.
15. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS 2011; 25:399-409.
16. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
17. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
18. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
19. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIVinfected patients. N Engl J Med 2004; 351:438-450. (Pubitemid 38988593)
20. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-459. (Pubitemid 38988594)
21. Morin T, Pariente A, Lahmek P, Rabaud C, Silvain C, Cadranel JF. Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort. Eur J Gastroenterol Hepatol 2010; 22:157-166.
22. Arends JE, van Assen S, Stek CJ, Wensing AM, Fransen JH, Schellens IM, et al. Pegylated interferon-alpha monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C. Antivir Ther 2011; 16:979-988.
23. Vogel M, Nattermann J, Baumgarten A, Klausen G, Bieniek B, Schewe K, et al. Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antivir Ther 2006; 11:1097-1101. (Pubitemid 44955186)
24. Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, Applegate T, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010; 52:1216-1224.
25. Darke S, Hall W, Wodak A, Heather N, Ward J. Development and validation of a multidimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br J Addict 1992; 87:733-742.
26. Grebely J, Matthews GV, Hellard M, Shaw D, van Beek I, Petoumenos K, et al. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol 2011; 55:76-85.
27. McGovern BH, Nagami EH, Birch CE, Bowen MJ, Reyor LL, Chung RT, et al. Rate of sustained virologic response in relation to baseline hepatitis C virus (HCV) RNA level and rapid virologic clearance in persons with acute HCV infection. J Infect Dis 2009; 200:877-881.
28. Piroth L, Larsen C, Binquet C, Alric L, Auperin I, Chaix ML, et al. Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study. Hepatology 2010; 52:1915-1921.
29. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436:967-972. (Pubitemid 41191673)
30. Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, Liang TJ. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011; 53:32-41.
31. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 2007; 46:1548-1563. (Pubitemid 350155537)
32. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37:1351-1358. (Pubitemid 36667315)
33. Feld JJ, Lutchman GA, Heller T, Hara K, Pfeiffer JK, Leff RD, et al. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 2010; 139:154-162; e154.
34. Dahari H, Ribeiro RM, Perelson AS. Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 2007; 46:16-21. (Pubitemid 47171916)
35. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125:80-88. (Pubitemid 36799109)